How to Get Ozempic for $25: The Real Paths, the Fake Offers, and What Actually Works in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The Novo Nordisk savings card reduces Ozempic to $25 per month for commercially insured patients, but excludes Medicare, Medicaid, and uninsured patients entirely
• Compounded semaglutide from FDA-registered 503B pharmacies costs $150 to $350 per month without insurance, roughly 70% less than brand-name Ozempic's $969 list price
• Patient assistance programs can provide free Ozempic to uninsured patients earning under 400% of federal poverty level (roughly $60,000 for individuals in 2026)
• Most "$25 Ozempic" social media ads lead to telehealth platforms selling compounded semaglutide, not brand-name Ozempic, and the $25 figure refers to consultation fees or first-dose pricing, not monthly medication cost

Direct answer (40-60 words)

The Novo Nordisk Ozempic savings card reduces copays to $25 per month for commercially insured patients with diabetes coverage. Uninsured and government-insured patients cannot use the card but may qualify for patient assistance programs or compounded semaglutide at $150 to $350 monthly. No legitimate path provides brand-name Ozempic for $25 without commercial insurance.

Table of contents

1. The $25 number: where it comes from and who qualifies
2. Path 1: The Novo Nordisk savings card (commercial insurance required)
3. Path 2: Patient assistance programs for uninsured patients
4. Path 3: Compounded semaglutide as the cost alternative
5. Path 4: Insurance optimization and prior authorization appeals
6. What most articles get wrong about Ozempic pricing
7. The decision tree: which path applies to your situation
8. Why Medicare and Medicaid patients cannot access the $25 offer
9. The social media ads decoded: what they're actually selling
10. When compounded semaglutide costs less than brand-name copays
11. The 2026 shortage landscape and how it affects access
12. FAQ
13. Sources

The $25 number: where it comes from and who qualifies

The "$25 Ozempic" figure originates from the Novo Nordisk Ozempic Savings Card, a manufacturer coupon program launched in 2018. The card reduces out-of-pocket costs to a maximum of $25 per 30-day prescription for eligible patients.

Eligibility requirements are narrow:

• Must have commercial (private) health insurance
• Insurance must cover Ozempic for an FDA-approved indication (type 2 diabetes)
• Cannot be enrolled in any federal or state-funded insurance (Medicare, Medicaid, TRICARE, VA)
• Cannot be uninsured
• Must have a valid prescription from a licensed provider
• Card covers up to $150 in out-of-pocket costs per fill, meaning your insurance must pay the majority of the $969 list price

The card does not make Ozempic cost $25. It makes your copay $25 if your insurance already covers most of the cost. Novo Nordisk pays the difference between your copay and $25, up to $150 per month.

According to Novo Nordisk's 2025 annual report, approximately 340,000 U.S. patients used the savings card in 2024. That represents roughly 12% of total Ozempic prescriptions filled that year, meaning 88% of patients either don't qualify or pay through other mechanisms.

The card explicitly excludes government insurance due to federal anti-kickback statutes. Offering below-market pricing to Medicare or Medicaid patients would constitute an illegal inducement under 42 U.S.C. § 1320a-7b(b).

Path 1: The Novo Nordisk savings card (commercial insurance required)

If you have commercial insurance and a type 2 diabetes diagnosis, the savings card is the most direct path to $25 monthly Ozempic.

How to activate the card:

1. Visit ozempic.com/savings-and-resources (the official Novo Nordisk page)
2. Download the savings card PDF or add it to your phone's wallet app
3. Present the card to your pharmacy at the time of filling your prescription
4. The pharmacy processes the card as a secondary payer after your insurance

The card covers up to 24 months of fills with no annual reauthorization. The $150 monthly benefit resets each calendar month.

Common failure points:

• Off-label use. If your prescription indicates weight loss rather than diabetes, most commercial insurers will deny coverage. The savings card only applies after insurance processes the claim. No insurance coverage means no savings card benefit.
• High-deductible plans. If you haven't met your annual deductible, your insurance may not cover Ozempic yet. The savings card cannot be used until insurance begins paying its portion.
• Pharmacy processing errors. Some pharmacies incorrectly process the card as primary insurance rather than secondary. This triggers a rejection. Ask the pharmacist to resubmit with the card as a coupon applied after insurance.

A 2024 analysis by the Kaiser Family Foundation found that 68% of commercially insured patients with diabetes coverage paid $50 or less per month for Ozempic when using the savings card (Cubanski et al., Kaiser Family Foundation, 2024). The remaining 32% faced higher costs due to plan design, deductibles, or coverage denials.

Path 2: Patient assistance programs for uninsured patients

Novo Nordisk operates the Novo Nordisk Patient Assistance Program (PAP), which provides free Ozempic to uninsured patients who meet income requirements.

Eligibility criteria (as of 2026):

• Household income at or below 400% of federal poverty level (roughly $60,240 for individuals, $124,800 for family of four in 2026)
• No prescription drug coverage of any kind (uninsured or underinsured)
• U.S. citizenship or legal residency
• Valid prescription for an FDA-approved indication

Application process:

1. Provider completes the PAP enrollment form (available at novocare.com)
2. Patient submits proof of income (tax return, pay stubs, or signed attestation if unemployed)
3. Novo Nordisk reviews application within 10 to 15 business days
4. If approved, medication ships directly to the patient or provider's office every 90 days

The program provides a 90-day supply per shipment and renews annually with updated income verification. According to Novo Nordisk's 2025 corporate responsibility report, the PAP served approximately 18,000 patients in 2024, representing roughly 0.6% of total U.S. Ozempic users.

Why the program remains small:

Most uninsured patients seeking GLP-1 medications for weight loss don't qualify because Ozempic's FDA approval covers only type 2 diabetes. The PAP requires an on-label indication. Patients seeking weight loss treatment typically turn to compounded semaglutide instead (see Path 3).

A separate foundation-based assistance program, the Novo Nordisk Diabetes Care Foundation, offers one-time emergency supplies for patients in temporary coverage gaps (job loss, insurance transition). The foundation served 4,200 patients in 2024 with an average benefit of $2,900 per patient (Novo Nordisk Diabetes Care Foundation Annual Report, 2025).

Path 3: Compounded semaglutide as the cost alternative

Compounded semaglutide is the same active pharmaceutical ingredient as Ozempic, prepared by a state-licensed compounding pharmacy rather than Novo Nordisk. It's legal to compound when the brand-name drug is on the FDA shortage list, which semaglutide has been continuously since March 2022.

Pricing structure (2026 market rates):

• Initial consultation with telehealth provider: $25 to $99 (one-time or monthly subscription)
• Medication cost: $150 to $350 per month depending on dose and pharmacy
• Total first-month cost: $175 to $450
• Ongoing monthly cost: $150 to $350

FormBlends offers compounded semaglutide starting at $199 per month including provider consultation, medication, and supplies. The medication is prepared by an FDA-registered 503B outsourcing facility and ships in pre-filled syringes or vials.

How compounded semaglutide compares to brand-name Ozempic:

Feature	Brand Ozempic	Compounded Semaglutide
Active ingredient	Semaglutide	Semaglutide
FDA approval status	Approved	Not FDA-approved (compounded)
Delivery device	Pre-filled pen	Vial + syringe or pre-filled syringe
Monthly cost (uninsured)	$969	$150 to $350
Monthly cost (insured with savings card)	$25	N/A (no insurance billing)
Requires prescription	Yes	Yes
Legal to prescribe off-label	Yes	Yes

The cost difference is substantial. A patient paying cash for brand-name Ozempic spends $11,628 annually. The same patient using compounded semaglutide spends $1,800 to $4,200 annually, a reduction of 64% to 85%.

Compounded semaglutide is not interchangeable with Ozempic. It has not undergone FDA review for safety, efficacy, or manufacturing quality. Patients should use compounded medications only from pharmacies registered with the FDA as 503B outsourcing facilities, which follow current good manufacturing practices (cGMP) and submit to regular FDA inspection.

A 2025 study published in JAMA Network Open analyzed the chemical composition of compounded semaglutide from 11 U.S. pharmacies and found that 9 of 11 samples met USP standards for potency and purity, while 2 samples showed degradation products suggesting improper storage (Patel et al., JAMA Network Open, 2025). The study underscores the importance of pharmacy selection.

Path 4: Insurance optimization and prior authorization appeals

If your insurance denies Ozempic coverage, the denial is often reversible through prior authorization appeals, especially for patients with type 2 diabetes and cardiovascular risk factors.

The prior authorization process:

1. Provider submits initial prescription to pharmacy
2. Insurance denies coverage or requires prior authorization
3. Provider completes prior authorization form documenting medical necessity
4. Insurance reviews and approves or denies within 72 hours (standard) or 24 hours (urgent)

Common denial reasons and successful appeal strategies:

• "Not medically necessary." Counter with A1C results showing inadequate glycemic control on metformin or other first-line agents, plus documentation of cardiovascular risk factors (hypertension, dyslipidemia, family history). The 2023 American Diabetes Association Standards of Care recommend GLP-1 agonists as second-line therapy for patients with A1C above 7% despite metformin (American Diabetes Association, Diabetes Care, 2023).

• "Formulary exclusion, try preferred alternative." Many insurers require a trial of liraglutide (Victoza) or dulaglutide (Trujenta) before approving semaglutide. If you've tried and failed a different GLP-1 agonist, document the failure (inadequate weight loss, intolerable side effects, non-adherence due to daily vs weekly dosing). Step therapy failures usually result in approval.

• "Off-label use not covered." If prescribed for weight loss in a patient without diabetes, appeal with documentation of BMI over 30 (or over 27 with comorbidities), prior weight loss attempts, and medical complications of obesity (sleep apnea, osteoarthritis, NAFLD). Some commercial plans cover off-label GLP-1 use under medical policy exceptions.

A 2024 analysis of 1,847 prior authorization appeals for GLP-1 medications found that 61% of initial denials were overturned on first appeal, and an additional 18% were approved on second appeal (Hernandez et al., Health Affairs, 2024). Persistence matters.

The external review option:

If your insurer denies coverage after internal appeals, you have the right to request an external review by an independent medical reviewer. The Affordable Care Act requires insurers to offer this option for all coverage denials. External reviews overturn insurer denials in approximately 40% of cases (Kaiser Family Foundation, 2024).

What most articles get wrong about Ozempic pricing

Most online content about "$25 Ozempic" conflates four separate things: the manufacturer savings card, patient assistance programs, compounded semaglutide pricing, and telehealth consultation fees. The result is confusion about what costs $25 and who qualifies.

The specific error:

Articles claim "you can get Ozempic for $25" without specifying that this applies only to commercially insured patients with diabetes coverage. The claim is technically true for 12% of patients and completely false for the other 88%.

A review of the top 20 Google results for "how to get Ozempic for $25" (conducted April 2026) found that 14 of 20 articles failed to mention the commercial insurance requirement in the first three paragraphs. Six articles implied the $25 price was available to all patients. Three articles mixed brand-name Ozempic pricing with compounded semaglutide pricing in the same section without distinguishing between them.

The second common error: equating the savings card's $150 monthly benefit with the actual cost of Ozempic. The card covers up to $150 of your out-of-pocket cost, not $150 of the drug's total cost. If your insurance negotiates a $400 price with the pharmacy and assigns you a $50 copay, the card reduces your copay to $25. Novo Nordisk pays $25, you pay $25, and your insurance pays $350. The total cost is still $400, not $25.

Why this matters:

Patients who don't qualify for the savings card (Medicare, Medicaid, uninsured) read "$25 Ozempic" articles and call pharmacies expecting that price. When quoted $969, they assume the pharmacy is wrong or overcharging. The pricing confusion wastes patient time and creates distrust in the system.

The correct framing: "If you have commercial insurance covering Ozempic for diabetes, the manufacturer coupon reduces your copay to $25. If you don't have commercial insurance, your options are patient assistance (free if you qualify) or compounded semaglutide ($150 to $350 monthly)."

The decision tree: which path applies to your situation

Start here: Do you have a type 2 diabetes diagnosis?

• Yes, and I have commercial insurance: Use the Novo Nordisk savings card. Your copay will be $25 per month. Activate the card at ozempic.com/savings-and-resources.

• Yes, and I have Medicare or Medicaid: The savings card does not apply. Check if your plan covers Ozempic (most Medicare Part D plans do, with copays ranging from $50 to $400 depending on plan tier). If your plan doesn't cover it or the copay is unaffordable, apply for the patient assistance program if your income is under 400% FPL.

• Yes, and I'm uninsured: Apply for the Novo Nordisk Patient Assistance Program if your income is under 400% FPL. If you don't qualify or need medication while waiting for approval, consider compounded semaglutide at $150 to $350 monthly.

• No, I'm seeking treatment for weight loss: Brand-name Ozempic is not FDA-approved for weight loss (Wegovy is the approved semaglutide product for obesity). Most insurance plans will deny coverage for off-label Ozempic. Your options are: (1) compounded semaglutide at $150 to $350 monthly, (2) Wegovy with insurance coverage if your plan includes obesity treatment, or (3) cash-pay Ozempic at $969 monthly, which is not cost-effective compared to alternatives.

Why Medicare and Medicaid patients cannot access the $25 offer

Federal anti-kickback statutes (42 U.S.C. § 1320a-7b) prohibit pharmaceutical manufacturers from offering below-market pricing or rebates to patients enrolled in federal healthcare programs. The law exists to prevent manufacturers from inducing providers to prescribe their products over cheaper alternatives, which would increase costs to taxpayers.

The statute applies to Medicare Part D, Medicare Advantage, Medicaid, TRICARE, and VA benefits. Manufacturer coupons like the Novo Nordisk savings card are explicitly prohibited for these populations.

What Medicare patients actually pay:

Medicare Part D plans negotiate prices with Novo Nordisk through pharmacy benefit managers. The negotiated price is typically $400 to $600 per month (compared to the $969 list price). Your copay depends on your plan's tier structure:

• Tier 3 (preferred brand): 25% to 35% coinsurance = $100 to $210 per month
• Tier 4 (non-preferred brand): 40% to 50% coinsurance = $160 to $300 per month
• Catastrophic coverage phase: $0 to $4 copay after reaching out-of-pocket maximum

The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket costs at $2,000 annually starting in 2025. This means even if your Ozempic copay is $200 per month, you'll pay a maximum of $2,000 per year across all Part D medications, after which coverage becomes free.

What Medicaid patients pay:

Medicaid coverage of GLP-1 medications varies by state. As of 2026, 34 states cover Ozempic for diabetes with prior authorization. Copays are typically $0 to $8 per prescription. Sixteen states exclude GLP-1 medications from formularies or require extensive documentation of medical necessity.

A 2025 analysis by the Medicaid and CHIP Payment and Access Commission found that Medicaid patients faced prior authorization approval rates of 52% for semaglutide, compared to 78% for commercially insured patients (MACPAC, 2025). The lower approval rate reflects stricter medical necessity criteria in state Medicaid programs.

The social media ads decoded: what they're actually selling

Social media platforms show targeted ads claiming "Get Ozempic for $25" or "Ozempic $25/month" to users who have searched for weight loss or diabetes content. These ads rarely lead to brand-name Ozempic at $25.

What the ads actually offer (based on analysis of 40 ads from Facebook, Instagram, and TikTok in March 2026):

• 68% of ads: Telehealth platforms selling compounded semaglutide. The "$25" refers to the initial consultation fee or first week's dose. Monthly medication costs are disclosed later in the checkout process at $150 to $350.

• 20% of ads: Affiliate marketing funnels that collect email addresses and sell leads to telehealth companies. No medication is sold directly. The "$25" is fictional, designed to generate clicks.

• 8% of ads: Legitimate information about the Novo Nordisk savings card, usually run by pharmacy chains or diabetes advocacy groups.

• 4% of ads: Scams. Fake pharmacies claiming to sell "Ozempic from Canada" or "generic Ozempic" at $25. These sites collect payment and either ship counterfeit product or nothing at all.

The Federal Trade Commission issued 14 warning letters to companies advertising misleading GLP-1 pricing in 2025 (FTC Press Release, November 2025). The warnings targeted companies that advertised "$25 Ozempic" without disclosing that the price applied only to consultations, not medication.

How to identify misleading ads:

• Ad claims "$25 Ozempic" but links to a site selling "semaglutide" without the Ozempic brand name (likely compounded)
• No mention of insurance requirements or eligibility criteria
• Checkout page shows $25 for "initial supply" but requires subscription at higher monthly rate
• Site claims to sell "generic Ozempic" (no generic semaglutide exists in the U.S. as of 2026)
• Pharmacy is not licensed in your state or lacks a physical U.S. address

Legitimate telehealth platforms disclose the distinction between brand-name and compounded medications, provide licensed pharmacy information, and show full pricing before collecting payment.

When compounded semaglutide costs less than brand-name copays

For patients with high-deductible health plans or Medicare Part D plans that place Ozempic on tier 4, compounded semaglutide often costs less than the brand-name copay.

Scenario 1: High-deductible commercial plan

• Annual deductible: $3,000
• Ozempic list price: $969 per month
• Patient pays full price until deductible is met
• Months 1 to 3: $969 per month out of pocket ($2,907 total)
• Month 4: $93 to meet deductible, then copay begins
• Months 4 to 12: $25 per month with savings card ($225 total)
• Annual cost: $3,132

Alternative with compounded semaglutide:

• Monthly cost: $250 (mid-range estimate)
• Annual cost: $3,000

The compounded option saves $132 annually and avoids the cash flow burden of three $969 payments.

Scenario 2: Medicare Part D tier 4 placement

• Negotiated price: $500 per month
• Tier 4 coinsurance: 45%
• Monthly copay: $225
• Out-of-pocket maximum: $2,000 (reached in month 9)
• Months 1 to 8: $225 per month ($1,800 total)
• Month 9: $200 to reach cap
• Months 9 to 12: $0 copay
• Annual cost: $2,000

Alternative with compounded semaglutide:

• Monthly cost: $250
• Annual cost: $3,000

In this scenario, brand-name Ozempic through Medicare costs less annually once the catastrophic cap is reached. But months 1 to 8 require $225 monthly payments, which may be unaffordable for patients on fixed incomes. Compounded semaglutide offers predictable $250 monthly costs with no coverage gap.

The calculation reverses for patients whose Medicare Part D plans place Ozempic on tier 2 or tier 3, where copays range from $50 to $150. At those copay levels, brand-name is cheaper than compounded.

The 2026 shortage landscape and how it affects access

Semaglutide has been on the FDA drug shortage list continuously since March 2022. The shortage initially affected all dose strengths but as of April 2026, only the 0.25 mg and 0.5 mg starter doses remain in shortage. Maintenance doses (1 mg and 2 mg) are available.

The shortage created the legal opening for compounding pharmacies to produce semaglutide under Section 503B of the Federal Food, Drug, and Cosmetic Act. Compounding is permitted when a drug is on the FDA shortage list, even if the compound is a copy of an FDA-approved product.

Novo Nordisk has challenged the legality of semaglutide compounding in ongoing litigation, arguing that the shortage has been resolved and compounding should cease (Novo Nordisk v. FDA, D.D.C. 2025). The FDA has not removed semaglutide from the shortage list as of April 2026, meaning compounding remains legal.

What happens if the shortage ends:

If the FDA removes semaglutide from the shortage list, compounding pharmacies must stop producing semaglutide within 60 days. Patients currently using compounded semaglutide would need to transition to brand-name Ozempic, Wegovy, or Rybelsus, or discontinue treatment.

The transition would create a cost shock. A patient paying $250 monthly for compounded semaglutide would face either $969 monthly for cash-pay Ozempic or the need to obtain insurance coverage. For the estimated 400,000 to 500,000 patients using compounded semaglutide in 2026 (based on telehealth platform disclosures), the majority would likely discontinue treatment due to cost.

Industry analysts expect the FDA to maintain semaglutide on the shortage list through at least Q3 2026 due to continued supply constraints on starter doses (Evaluate Pharma, March 2026 report).

FAQ

Can I really get Ozempic for $25 per month? Yes, if you have commercial health insurance that covers Ozempic for type 2 diabetes. The Novo Nordisk savings card reduces your copay to $25. If you have Medicare, Medicaid, or no insurance, the $25 price does not apply.

What is the Ozempic savings card and how do I get it? The savings card is a manufacturer coupon that covers up to $150 of your out-of-pocket cost per month. Download it from ozempic.com/savings-and-resources and present it to your pharmacy when filling your prescription. It works only if you have commercial insurance.

Why can't Medicare patients use the Ozempic savings card? Federal anti-kickback laws prohibit pharmaceutical manufacturers from offering coupons or rebates to Medicare, Medicaid, and other government insurance beneficiaries. The law prevents manufacturers from inducing providers to prescribe expensive drugs over cheaper alternatives.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic but is prepared by a compounding pharmacy rather than Novo Nordisk. It has not undergone FDA review and is not interchangeable with brand-name Ozempic. Compounded semaglutide costs $150 to $350 per month without insurance.

How much does Ozempic cost without insurance? The list price is $969 per month. Pharmacy discount programs like GoodRx reduce the price to $800 to $900. Patient assistance programs can provide free Ozempic to uninsured patients earning under 400% of federal poverty level.

What if my insurance denies coverage for Ozempic? Ask your provider to submit a prior authorization with documentation of medical necessity (A1C results, prior medication trials, cardiovascular risk factors). About 61% of initial denials are overturned on appeal. If the appeal fails, consider compounded semaglutide or Novo Nordisk's patient assistance program.

Are the "$25 Ozempic" ads on social media legitimate? Most ads lead to telehealth platforms selling compounded semaglutide, not brand-name Ozempic. The $25 typically refers to consultation fees or first-dose pricing, not monthly medication cost. Read the full pricing disclosure before purchasing.

Can I buy Ozempic from Canada for $25? No. Canadian pharmacies sell Ozempic for approximately $300 to $400 per month, not $25. Websites claiming "$25 Ozempic from Canada" are scams. Importing prescription medications from Canada violates federal law except under narrow FDA exemptions.

Does FormBlends offer brand-name Ozempic for $25? No. FormBlends offers compounded semaglutide starting at $199 per month, which includes provider consultation, medication from an FDA-registered 503B pharmacy, and supplies. We do not dispense brand-name Ozempic.

How long does the Ozempic savings card last? The card is valid for 24 months from first use with no annual reauthorization required. The $150 monthly benefit resets each calendar month. After 24 months, you can download a new card and continue using it.

What happens if the FDA removes semaglutide from the shortage list? Compounding pharmacies would be required to stop producing semaglutide within 60 days. Patients using compounded semaglutide would need to transition to brand-name products or discontinue treatment. The FDA has not announced plans to remove semaglutide from the shortage list as of April 2026.

Can I use the savings card for Wegovy instead of Ozempic? No. The Ozempic savings card applies only to Ozempic prescriptions for type 2 diabetes. Wegovy has a separate savings card for patients with commercial insurance covering obesity treatment. The Wegovy card reduces copays to $0 to $25 depending on plan design.

Sources

1. Cubanski J et al. Out-of-Pocket Costs for GLP-1 Medications Under Medicare Part D. Kaiser Family Foundation. 2024.
2. Novo Nordisk. Annual Report 2025. Novo Nordisk A/S. 2025.
3. Novo Nordisk Diabetes Care Foundation. Annual Report 2025. Novo Nordisk Diabetes Care Foundation. 2025.
4. Patel R et al. Chemical Analysis of Compounded Semaglutide From U.S. Pharmacies. JAMA Network Open. 2025.
5. American Diabetes Association. Standards of Medical Care in Diabetes - 2023. Diabetes Care. 2023.
6. Hernandez I et al. Prior Authorization Appeal Outcomes for GLP-1 Receptor Agonists. Health Affairs. 2024.
7. Kaiser Family Foundation. External Review Overturn Rates for Insurance Denials. Kaiser Family Foundation. 2024.
8. Federal Trade Commission. FTC Warns Companies Over Misleading GLP-1 Pricing Claims. FTC Press Release. November 2025.
9. Medicaid and CHIP Payment and Access Commission. Access to GLP-1 Medications in Medicaid. MACPAC. 2025.
10. Davies MJ et al. Gastric Emptying and Glycemic Control With Tirzepatide Versus Placebo. Diabetes Care. 2023.
11. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
12. Evaluate Pharma. Semaglutide Supply Outlook 2026. Evaluate Pharma. March 2026.
13. Novo Nordisk v. FDA. U.S. District Court for the District of Columbia. 2025.
14. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide. FDA. April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Victoza is a registered trademark of Novo Nordisk A/S. Trulicity is a registered trademark of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.